BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit (PRNewswire) - May 6, 2025 - "BrainStorm Cell Therapeutics Inc...announced its participation in the 4th Annual ALS Drug Development Summit, to take place May 12-14, 2025, in Boston, MA. The company's senior leadership team will participate in sessions that highlight insights and expertise gained throughout the NurOwn development program, contributing to the broader conversation on the future of ALS clinical research. Netta Blondheim-Shraga, PhD, Senior Vice President of Research & Development at BrainStorm, will present new insights into cerebrospinal fluid (CSF) biomarker pathways associated with Debamestrocel (NurOwn), the company's investigational cell therapy, including their relationship to clinical outcomes and disease heterogeneity in ALS."
Clinical • Amyotrophic Lateral Sclerosis
|